Barclays’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Barclays’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-43,633	Closed	-$871K	–	5607
2022 Q3	$871K	Buy	43,633 +29,980	+220%	+$395K	﹤0.01%	2339
2022 Q2	$94K	Buy	13,653 +4,946	+57%	+$34.7K	﹤0.01%	3792
2022 Q1	$82K	Buy	+8,707	New	+$92.7K	﹤0.01%	3882

Barclays's FMTX Position: Q4 2022 in Review

Barclays sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 43,633 shares — an estimated $871K sold.

Barclays first reported a position in FMTX in Q1 2022 and held it in 3 quarters. The position peaked at $871K in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Barclays reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Barclays sold 43,633 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $871K.
Barclays first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Barclays's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $871K in Q3 2022.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.